Zealand Pharma sends obesity candidate to clinic
Zealand Pharma has started a phase I study of the drug candidate ZP8396, which the company hopes will become an effective treatment for obesity. The trial is expected to be finished in September 2022.
by albert rønning-andersen, translated by catherine brett
Danish pharmaceutical company Zealand Pharma wants a slice of the lucrative market for obesity treatments.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk hires Queen Latifah for US marketing offensive
For subscribers
.jpg&w=384&q=75)
